What to expect from risk-reducing endocrine therapy for a BRCA gene mutation

Endocrine therapy lowers the effect of hormones on hormone-sensitive breast tissue. It may be discussed as part of a wider risk-reduction plan after your personal and family history, genetic result, age, reproductive plans and existing health conditions are reviewed. A BRCA1 or BRCA2 result does not by itself determine whether this medicine is suitable.

The medicine may be taken as a tablet on a schedule set by your clinician. Possible effects include hot flushes, night sweats, mood or sleep changes, vaginal dryness and changes in menstrual bleeding. Some medicines affect bone strength or blood-clot risk, so your team considers your medical history and may arrange monitoring.

Take the medicine exactly as prescribed and ask what to do after a missed dose. Before starting, share a full list of medicines, supplements and health conditions, including clotting problems, bone concerns, liver disease and pregnancy plans. Do not stop treatment because of a troublesome effect without contacting the prescribing team; alternatives or supportive care may be available.

Keep recommended breast imaging, genetic counselling and prevention appointments. Ask whether bone health checks, gynaecological review or contraception advice apply to you. Report side effects in a brief diary so the team can weigh day-to-day impact against the intended risk reduction.

Seek urgent help for sudden chest pain, shortness of breath, coughing blood, or new one-sided leg swelling and pain, which can signal a blood clot. Contact your clinician promptly for heavy unexpected bleeding, severe depression, yellowing of the skin, or any suspected pregnancy while taking the medicine.

Ask which endocrine medicine is being considered, how it fits with screening and other risk-reduction choices, and how long the planned course may be. Discuss fertility, contraception, menopause symptoms, bone health, clot risk, interactions and what follow-up will measure.